Remove express-pharma-magazine
article thumbnail

FDA approves MSD’s Keytruda to treat head and neck cancer

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”? This is intended for adults whose tumours express PD-L1 with a combined positive score [CPS] ≥1 as measured by a test approved by the US regulator. Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells.

article thumbnail

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”? This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

RFK Jr axes vaccine advisory committee members

Pharmaceutical Technology

Can pharma tariffs “Make America Manufacture Again”? APhA said it had decided to “withhold endorsing the current ACIP Adult Immunization Schedule issued on May 28, 2025″ The major shake-up to the schedule came via a video announcement from RFK Jr. lev radin via Shutterstock.

article thumbnail

Teva and Fosun Pharma partner on early-stage oncology drug

Pharma Times

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T cells within the tumour microenvironment, with the goal of amplifying anti-tumour T-cell activity while minimising systemic toxicities.

article thumbnail

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

pharmaphorum

billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. Inobrodib works by targeting twin cancer proteins p300 and CBP, which impacts the expression of cancer drivers including MYC and IRF4.